1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer

How to hijack degrading complexes to put cancer cells asleep


Researchers uncover an alternative path of how the breast cancer drug palbociclib drives malignant cells into senescence


Heidelberg, 23 April 2018 - Palbociclib is a drug used for the treatment of advanced estrogen-receptor-positive breast cancer. It induces cell cycle arrest and senescence, an irreversible resting state marking these ‘out-of-order’ cells to be cleared by the immune system. Notably, the mechanistic details of how palbociclib drives cancer cells into senescence are largely unknown to date. Researchers at the Universities of Dundee and Newcastle and their colleagues now investigated the drug’s mode of action in more detail and uncovered the proteasome, a cellular degradation machinery vital for the control of cell proliferation, as its yet unknown target. Their discovery could potentially help expand palbociclib-based breast cancer treatments and identify patients that would profit most from this medication. The research was published in The EMBO Journal.


A new blood test useful to detect people at risk of developing Alzheimer’s disease


Heidelberg, 6 April 2018 −There is as yet no cure for Alzheimer’s disease. It is often argued that progress in drug research has been hampered by the fact that the disease can only be diagnosed when it is too late for an effective intervention. Alzheimer’s disease is thought to begin long before patients show typical symptoms like memory loss. Scientists have now developed a blood test for Alzheimer’s disease and found that it can detect early indicators of the disease long before the first symptoms appear in patients. The blood test would thus offer an opportunity to identify those at risk and may thereby open the door to new avenues in drug discovery. The research is published today in EMBO Molecular Medicine.


Not-for-profit publishers partner to launch new research journal Life Science Alliance


EMBO Press, Rockefeller University Press and Cold Spring Harbor Laboratory Press join forces to empower authors to publish new research more efficiently


Heidelberg, New York, and Cold Spring Harbor, 3 April 2018 EMBO Press, Rockefeller University Press, and Cold Spring Harbor Laboratory Press today announce the launch of Life Science Alliance, a new global, open access, editorially independent, peer-reviewed journal committed to rapid, fair and transparent publication of valuable research from across the life sciences. Manuscripts can be submitted to Life Science Alliance directly or by seamless transfer without reformatting from nine partner journals: The EMBO Journal, EMBO Reports, Molecular Systems Biology, EMBO Molecular Medicine, Journal of Cell Biology, Journal of Experimental Medicine, Journal of General Physiology, Genes & Development, and Genome Research.


Frauke Melchior receives the 2018 FEBS | EMBO Women in Science Award


Heidelberg, 20 February 2018 – EMBO and the Federation of European Biochemical Societies (FEBS) announce Frauke Melchior from the Center for Molecular Biology (ZMBH) at Heidelberg University, Germany, as the recipient of the 2018 FEBS | EMBO Women in Science Award.